On the public citation graph

Trial of Anifrolumab in Active Systemic Lupus Erythematosus

https://doi.org/10.1056/nejmoa1912196
0 signed · 1411 inferred · view as graph

Inferred edges come from two machine sources: sweeps of open repository metadata (mostly SSRN and Zenodo), and a bulk OpenAlex citation snapshot. Every row below is labelled with the one it came from. Neither is a complete citation index — absence here is not evidence of absence.

Is this your work? Sign in with ORCID and put your name on the claims that are yours.
Claim with ORCID
Reference health. See whether every reference in this work resolves to a known work and none has been retracted — and get a dated CiteStamped badge you can embed.
See reference health

What this work says

Outgoing claims: the papers this work cites, builds on, or argues with.

inferredcites →https://doi.org/10.1002/art.1780400928openalex-snapshot
Updating the American college of rheumatology revised criteria for the classification of systemic lupus erythematosus
inferredcites →https://doi.org/10.1002/art.21571openalex-snapshot
The type I interferon system in systemic lupus erythematosus
inferredcites →https://doi.org/10.1002/art.24698openalex-snapshot
Novel evidence‐based systemic lupus erythematosus responder index
inferredcites →https://doi.org/10.1002/art.30613openalex-snapshot
A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus
inferredcites →https://doi.org/10.1002/art.39962openalex-snapshot
Anifrolumab, an Anti–Interferon‐α Receptor Monoclonal Antibody, in Moderate‐to‐Severe Systemic Lupus Erythematosus
inferredcites →https://doi.org/10.1002/sim.3513openalex-snapshot
A recycling framework for the construction of Bonferroni‐based multiple tests
inferredcites →https://doi.org/10.1016/b978-0-323-04434-9.50060-9openalex-snapshot
SYSTEMIC LUPUS ERYTHEMATOSUS DISEASE ACTIVITY INDEX
inferredcites →https://doi.org/10.1016/j.berh.2017.10.003openalex-snapshot
Role of interferons in SLE
inferredcites →https://doi.org/10.1016/j.cell.2016.03.008openalex-snapshot
Personalized Immunomonitoring Uncovers Molecular Networks that Stratify Lupus Patients
inferredcites →https://doi.org/10.1016/j.cell.2016.05.057openalex-snapshot
Personalized Immunomonitoring Uncovers Molecular Networks that Stratify Lupus Patients
inferredcites →https://doi.org/10.1016/s0140-6736(10)61354-2openalex-snapshot
Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial
inferredcites →https://doi.org/10.1016/s0197-2456(96)00129-8openalex-snapshot
Some statistical methods for multiple endpoints in clinical trials
inferredcites →https://doi.org/10.1016/s2665-9913(19)30076-1openalex-snapshot
Type I interferon inhibitor anifrolumab in active systemic lupus erythematosus (TULIP-1): a randomised, controlled, phase 3 trial
inferredcites →https://doi.org/10.1038/nbt0119-7openalex-snapshot
Lupus in crisis: as failures pile up, clinicians call for new tools
inferredcites →https://doi.org/10.1038/nrrheum.2015.86openalex-snapshot
The evolution of drug discovery in systemic lupus erythematosus
inferredcites →https://doi.org/10.1056/nejm197907053010102openalex-snapshot
Immune Interferon in the Circulation of Patients with Autoimmune Disease
inferredcites →https://doi.org/10.1056/nejmoa051135openalex-snapshot
Combined Oral Contraceptives in Women with Systemic Lupus Erythematosus
inferredcites →https://doi.org/10.1093/rheumatology/keg382openalex-snapshot
Definition and treatment of lupus flares measured by the BILAG index
inferredcites →https://doi.org/10.1093/rheumatology/keh624openalex-snapshot
BILAG 2004. Development and initial validation of an updated version of the British Isles Lupus Assessment Group's disease activity index for patients with systemic lupus erythematosus
inferredcites →https://doi.org/10.1093/rheumatology/keq026openalex-snapshot
Numerical scoring for the BILAG-2004 index
inferredcites →https://doi.org/10.1111/j.0022-202x.2005.23889.xopenalex-snapshot
The CLASI (Cutaneous Lupus Erythematosus Disease Area and Severity Index): An Outcome Instrument for Cutaneous Lupus Erythematosus
inferredcites →https://doi.org/10.1136/annrheumdis-2012-202760openalex-snapshot
Efficacy and safety of epratuzumab in patients with moderate/severe active systemic lupus erythematosus: results from EMBLEM, a phase IIb, randomised, double-blind, placebo-controlled, multicentre study
inferredcites →https://doi.org/10.1136/annrheumdis-2013-205171openalex-snapshot
Factors associated with damage accrual in patients with systemic lupus erythematosus: results from the Systemic Lupus International Collaborating Clinics (SLICC) Inception Cohort
inferredcites →https://doi.org/10.1136/annrheumdis-2014-206090openalex-snapshot
A Phase II study of the efficacy and safety of rontalizumab (rhuMAb interferon-α) in patients with systemic lupus erythematosus (ROSE)
inferredcites →https://doi.org/10.1136/annrheumdis-2015-208562openalex-snapshot
Sifalimumab, an anti-interferon-α monoclonal antibody, in moderate to severe systemic lupus erythematosus: a randomised, double-blind, placebo-controlled study
inferredcites →https://doi.org/10.1136/lupus-2013-000005openalex-snapshot
Which outcome measures in SLE clinical trials best reflect medical judgment?
inferredcites →https://doi.org/10.1136/lupus-2018-000261openalex-snapshot
Characterisation of anifrolumab, a fully human anti-interferon receptor antagonist antibody for the treatment of systemic lupus erythematosus
inferredcites →https://doi.org/10.1186/ar2887openalex-snapshot
Use of type I interferon-inducible mRNAs as pharmacodynamic markers and potential diagnostic markers in trials with sifalimumab, an anti-IFNα antibody, in systemic lupus erythematosus
inferredcites →https://doi.org/10.1186/s13075-015-0702-6openalex-snapshot
Measuring disease activity in adults with systemic lupus erythematosus: the challenges of administrative burden and responsiveness to patient concerns in clinical research
inferredcites →https://doi.org/10.4061/2009/374312openalex-snapshot
Development of Potential Pharmacodynamic and Diagnostic Markers for Anti-IFN-α Monoclonal Antibody Trials in Systemic Lupus Erythematosus

What points at this work

Incoming claims: where this work appears in other papers’ reference lists and arguments.

inferred← citeshttps://doi.org/10.2139/ssrn.4468414openalex-extracted
Newly Diagnosed Systemic Lupus Erythematosus after Sars-Cov-2 Vaccination: Coincidental or Relevant?
inferred← citeshttps://doi.org/10.2139/ssrn.4663953openalex-extracted
An Unconventional Mechanism of IL-1β Secretion that Requires Type I IFN in SLE Monocytes
inferred← citeshttps://doi.org/10.1001/jama.2024.2315openalex-snapshot
Systemic Lupus Erythematosus
inferred← citeshttps://doi.org/10.1001/jamadermatol.2023.0175openalex-snapshot
Assessment of Clinical Response to Anifrolumab in Patients With Refractory Discoid Lupus Erythematosus
inferred← citeshttps://doi.org/10.1001/jamadermatol.2025.1697openalex-snapshot
Nonlesional Skin and Blood Interferon Scores Among Patients With a History of Cutaneous Lupus
inferred← citeshttps://doi.org/10.1001/jamadermatol.2025.5920openalex-snapshot
SIGLEC-1 Expression in a Cohort of Patients With Lupus Erythematosus Treated With Anifrolumab
inferred← citeshttps://doi.org/10.1001/jamanetworkopen.2023.38200openalex-snapshot
Anifrolumab for Adolescent Discoid Lupus Erythematosus
inferred← citeshttps://doi.org/10.1001/jamanetworkopen.2025.60167openalex-snapshot
Cost-Effectiveness of Early vs Delayed Belimumab Treatment for Systemic Lupus Erythematosus
inferred← citeshttps://doi.org/10.1002/9781119709268.rook051openalex-snapshot
Lupus Erythematosus and Antiphospholipid Syndrome
inferred← citeshttps://doi.org/10.1002/acr.24221openalex-snapshot
Measures of Adult Systemic Lupus Erythematosus: Disease Activity and Damage
inferred← citeshttps://doi.org/10.1002/acr.24544openalex-snapshot
High Disease Severity Among Asian Patients in a US Multiethnic Cohort of Individuals With Systemic Lupus Erythematosus
inferred← citeshttps://doi.org/10.1002/acr.24606openalex-snapshot
Comparison of Responsiveness of British Isles Lupus Assessment Group 2004 Index, Systemic Lupus Erythematosus Disease Activity Index 2000, and British Isles Lupus Assessment Group 2004 Systems Tally
inferred← citeshttps://doi.org/10.1002/acr.25108openalex-snapshot
RheumMadness: Creating an Online Community of Inquiry in Rheumatology
inferred← citeshttps://doi.org/10.1002/acr.25640openalex-snapshot
Prevalence, Determinants, and Outcomes of Low Disease Activity and Remission Attainment in Patients With Systemic Lupus Erythematosus That Is Clinically Active
inferred← citeshttps://doi.org/10.1002/acr.25690openalex-snapshot
2025 American College of Rheumatology ( ACR ) Guideline for the Treatment of Systemic Lupus Erythematosus
inferred← citeshttps://doi.org/10.1002/acr2.11414openalex-snapshot
Interferon Inhibition for Lupus with Anifrolumab: Critical Appraisal of the Evidence Leading to FDA Approval
inferred← citeshttps://doi.org/10.1002/acr2.11594openalex-snapshot
Identifying lupus Patient Subsets Through Immune Cell Deconvolution of Gene Expression Data in Two Atacicept Phase II Studies
inferred← citeshttps://doi.org/10.1002/acr2.11618openalex-snapshot
Type 1 Interferon‐Stimulated Gene Expression and Disease Activity in Pediatric Rheumatic Diseases: No Composite Scores Needed?
inferred← citeshttps://doi.org/10.1002/acr2.70007openalex-snapshot
Frequency and Determinants of Flare and Persistently Active Disease in a Large Multinational Prospective Lupus Cohort
inferred← citeshttps://doi.org/10.1002/acr2.70165openalex-snapshot
Type I Interferon Gene Expression and Its Association With Ocular Involvement in Systemic Lupus Erythematosus
inferred← citeshttps://doi.org/10.1002/acr2.90002openalex-snapshot
Pretreatment Cytokine Signatures as Candidate Biomarkers for JAK Inhibitor Response in Anti‐ MDA5 Dermatomyositis–Related Interstitial Lung Disease: A Pilot Study
inferred← citeshttps://doi.org/10.1002/acr2.90065openalex-snapshot
Long‐Term Anifrolumab Treatment Normalizes Hematologic Parameters and Several Serologic Markers in Patients With Systemic Lupus Erythematosus
inferred← citeshttps://doi.org/10.1002/acr2.90071openalex-snapshot
Anifrolumab Plus Standard of Care Reduces Long‐Term Cardiovascular Damage in Adults With Systemic Lupus Erythematosus: Findings From a Real‐World External Control Study
inferred← citeshttps://doi.org/10.1002/advs.202500942openalex-snapshot
Type I Interferon Signaling Augments Autoimmunity in Neuromyelitis Optica Spectrum Disorder
inferred← citeshttps://doi.org/10.1002/art.41261openalex-snapshot
A Tale of Two Trials
inferred← citeshttps://doi.org/10.1002/art.41395openalex-snapshot
Low‐Density Neutrophils in Systemic Lupus Erythematosus
inferred← citeshttps://doi.org/10.1002/art.41419openalex-snapshot
Taurine Metabolism Aggravates the Progression of Lupus by Promoting the Function of Plasmacytoid Dendritic Cells
inferred← citeshttps://doi.org/10.1002/art.41478openalex-snapshot
Reply
inferred← citeshttps://doi.org/10.1002/art.41480openalex-snapshot
Expert Perspective: An Evidence‐Based Approach to Refractory Cutaneous Lupus Erythematosus
inferred← citeshttps://doi.org/10.1002/art.41489openalex-snapshot
Improvement of Severe Fatigue Following Nuclease Therapy in Patients With Primary Sjögren’s Syndrome: A Randomized Clinical Trial
inferred← citeshttps://doi.org/10.1002/art.41532openalex-snapshot
Type I Interferon–Activated STAT4 Regulation of Follicular Helper T Cell–Dependent Cytokine and Immunoglobulin Production in Lupus
inferred← citeshttps://doi.org/10.1002/art.41778openalex-snapshot
What Does It Mean to Be a British Isles Lupus Assessment Group–Based Composite Lupus Assessment Responder? Post Hoc Analysis of Two Phase III Trials
inferred← citeshttps://doi.org/10.1002/art.41810openalex-snapshot
What Did Not Work: The Drug or the Trial?
inferred← citeshttps://doi.org/10.1002/art.41811openalex-snapshot
Efficacy, Safety, and Pharmacodynamic Effects of the Bruton’s Tyrosine Kinase Inhibitor Fenebrutinib (GDC‐0853) in Systemic Lupus Erythematosus: Results of a Phase II, Randomized, Double‐Blind, Placebo‐Controlled Trial
inferred← citeshttps://doi.org/10.1002/art.42092openalex-snapshot
Expert Perspective: An Approach to Refractory Lupus Nephritis
inferred← citeshttps://doi.org/10.1002/art.42248openalex-snapshot
Longitudinal Immune Cell Profiling in Patients With Early Systemic Lupus Erythematosus
inferred← citeshttps://doi.org/10.1002/art.42350openalex-snapshot
Association of Modified Systemic Lupus Erythematosus Responder Index Attainment With Long‐Term Clinical Outcomes: A Five‐Year Prospective Study
inferred← citeshttps://doi.org/10.1002/art.42383openalex-snapshot
Dampened Inflammation and Improved Survival After CXCL5 Administration in Murine Lupus via Myeloid and Neutrophil Pathways
inferred← citeshttps://doi.org/10.1002/art.42391openalex-snapshot
Deucravacitinib, a Tyrosine Kinase 2 Inhibitor, in Systemic Lupus Erythematosus: A Phase II , Randomized, Double‐Blind , Placebo‐Controlled Trial
inferred← citeshttps://doi.org/10.1002/art.42392openalex-snapshot
A Randomized, Placebo‐Controlled Phase III Extension Trial of the Long‐Term Safety and Tolerability of Anifrolumab in Active Systemic Lupus Erythematosus
inferred← citeshttps://doi.org/10.1002/art.42462openalex-snapshot
Povetacicept, an Enhanced Dual APRIL / BAFF Antagonist That Modulates B Lymphocytes and Pathogenic Autoantibodies for the Treatment of Lupus and Other B Cell–Related Autoimmune Diseases
inferred← citeshttps://doi.org/10.1002/art.42485openalex-snapshot
Lupus Interference With B Cell Tolerance Across the Developmental Continuum
inferred← citeshttps://doi.org/10.1002/art.42652openalex-snapshot
Obexelimab in Systemic Lupus Erythematosus With Exploration of Response Based on Gene Pathway Co‐Expression Patterns: A Double‐Blind , Randomized, Placebo‐Controlled , Phase 2 Trial
inferred← citeshttps://doi.org/10.1002/art.42657openalex-snapshot
Safety and Efficacy of Long‐Term Voclosporin Treatment for Lupus Nephritis in the Phase 3 AURORA 2 Clinical Trial
inferred← citeshttps://doi.org/10.1002/art.42750openalex-snapshot
Single‐Cell Profiling of Bone Marrow B Cells and Early B Cell Developmental Disorders Associated With Systemic Lupus Erythematosus
inferred← citeshttps://doi.org/10.1002/art.42789openalex-snapshot
Association of Combined Anti‐Ro52 / TRIM21 and Anti‐Ro60 / SSA Antibodies With Increased Sjögren Disease Severity Through Interferon Pathway Activation
inferred← citeshttps://doi.org/10.1002/art.42849openalex-snapshot
Standing on Shoulders: Interferon Research From Viral Interference to Lupus Pathogenesis and Treatment
inferred← citeshttps://doi.org/10.1002/art.42863openalex-snapshot
Unique Interplay Between Antinuclear Antibodies and Nuclear Molecules in the Pathogenesis of Systemic Lupus Erythematosus
inferred← citeshttps://doi.org/10.1002/art.42926openalex-snapshot
Efficacy and Safety of Upadacitinib or Elsubrutinib Alone or in Combination for Patients With Systemic Lupus Erythematosus: A Phase 2 Randomized Controlled Trial
inferred← citeshttps://doi.org/10.1002/art.42983openalex-snapshot
Understanding the Role of Type I Interferons in Cutaneous Lupus and Dermatomyositis: Toward Better Therapeutics
inferred← citeshttps://doi.org/10.1002/art.43079openalex-snapshot
Topical Mupirocin Treatment Reduces Interferon and Myeloid Signatures in Cutaneous Lupus Erythematous Lesions Through Targeting of Staphylococcus Species
inferred← citeshttps://doi.org/10.1002/art.43108openalex-snapshot
Induction of Type I Interferon–Dependent Activation and Migration of Inflammatory Dendritic Cells to Local Lymph Nodes by UV Light Exposure
inferred← citeshttps://doi.org/10.1002/art.43145openalex-snapshot
Sustained Interferon Signature Suppression With Anifrolumab in a Patient With STING‐Associated Vasculopathy with Onset in Infancy Refractory to JAK Inhibitor and Dazukibart Therapy
inferred← citeshttps://doi.org/10.1002/art.43271openalex-snapshot
Pharmacodynamic Effects of Litifilimab in Lupus in a Randomized, Placebo‐Controlled Phase 2 Study: Rapid and Sustained Reductions in Type I Interferon‐Associated Gene Expression and Cytokines
inferred← citeshttps://doi.org/10.1002/art.43391openalex-snapshot
A Randomized, Placebo‐Controlled Trial of Hydroxychloroquine in Incomplete Lupus
inferred← citeshttps://doi.org/10.1002/art.43452openalex-snapshot
2025 American College of Rheumatology ( ACR ) Guideline for the Treatment of Systemic Lupus Erythematosus
inferred← citeshttps://doi.org/10.1002/art.70041openalex-snapshot
Efficacy and Safety of Subcutaneous Anifrolumab in Systemic Lupus Erythematosus: A Randomized, Phase 3 Study
inferred← citeshttps://doi.org/10.1002/art.70105openalex-snapshot
Multi‐Omic Profiling Reveals Immune Cell Priming Signature Linked to Lupus Prognosis
inferred← citeshttps://doi.org/10.1002/art.70225openalex-snapshot
“More guidelines than rules”: reconsidering key gaps in the 2025 American College of Rheumatology treatment recommendations for systemic lupus erythematosus: comment on the article by Sammaritano et al
inferred← citeshttps://doi.org/10.1002/art.70257openalex-snapshot
From Interferon Signature to the Clinical Landscape: Type I Interferonopathies
inferred← citeshttps://doi.org/10.1002/cpdd.887openalex-snapshot
Safety, Tolerability, and Pharmacokinetics of PF‐06823859, an Anti–Interferon β Monoclonal Antibody: A Randomized, Phase I, Single‐ and Multiple‐Ascending‐Dose Study
inferred← citeshttps://doi.org/10.1002/cpt.3282openalex-snapshot
B‐ and T‐Lymphocyte Attenuator in Systemic Lupus Erythematosus Disease Pathogenesis
inferred← citeshttps://doi.org/10.1002/cpt.70307openalex-snapshot
Anifrolumab Dose Regimen Selection for a Phase 3 Trial in Lupus Nephritis
inferred← citeshttps://doi.org/10.1002/cti2.1139openalex-snapshot
Plasmacytoid dendritic cell biology and its role in immune‐mediated diseases
inferred← citeshttps://doi.org/10.1002/cti2.1502openalex-snapshot
Chimeric antigen receptor T cells in the fast lane among autoimmune disease therapies
inferred← citeshttps://doi.org/10.1002/eji.202250197openalex-snapshot
Translational immunology: Applying fundamental discoveries to human health and autoimmune diseases
inferred← citeshttps://doi.org/10.1002/eji.70160openalex-snapshot
Systemic Type I Interferon Blockade Mitigates Insulin Resistance in a Preclinical Model of Psoriasis
inferred← citeshttps://doi.org/10.1002/jcph.2054openalex-snapshot
Relationship Between Anifrolumab Pharmacokinetics, Pharmacodynamics, and Efficacy in Patients With Moderate to Severe Systemic Lupus Erythematosus
inferred← citeshttps://doi.org/10.1002/jcph.2055openalex-snapshot
Nonlinear Population Pharmacokinetics of Anifrolumab in Healthy Volunteers and Patients With Systemic Lupus Erythematosus
inferred← citeshttps://doi.org/10.1002/jcph.6117openalex-snapshot
First‐in‐Human Study of the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Pharmacodynamics of DS‐7011a, an Anti‐TLR7 Antagonistic Monoclonal Antibody for the Treatment of Systemic Lupus Erythematosus
inferred← citeshttps://doi.org/10.1002/jlb.2mr0420-152ropenalex-snapshot
Structural integrity with functional plasticity: what type I IFN receptor polymorphisms reveal
inferred← citeshttps://doi.org/10.1002/jmv.70785openalex-snapshot
Epstein‐Barr Virus (EBV) and Autoimmune Diseases: Pathogenic Mechanisms and Therapeutic Insights
inferred← citeshttps://doi.org/10.1002/jmv.70928openalex-snapshot
What Roles Does EBV Play in Systemic Lupus Erythematosus? A Synthesis of Its Action Mechanisms
inferred← citeshttps://doi.org/10.1002/jvc2.590openalex-snapshot
Rapid clearance of cutaneous lesions with anifrolumab in SLE (systemic lupus erythematosus) and DLE (discoid lupus erythematosus)
inferred← citeshttps://doi.org/10.1002/psp4.12888openalex-snapshot
Disease trajectory of SLE clinical endpoints and covariates affecting disease severity and probability of response: Analysis of pooled patient‐level placebo ( Standard‐of‐Care ) data to enable model‐informed drug development
inferred← citeshttps://doi.org/10.1002/psp4.12982openalex-snapshot
Population pharmacokinetics of atacicept in systemic lupus erythematosus: An analysis of three clinical trials
inferred← citeshttps://doi.org/10.1002/psp4.13083openalex-snapshot
Model‐based meta‐analysis using latent variable modeling to set benchmarks for new treatments of systemic lupus erythematosus
inferred← citeshttps://doi.org/10.1002/psp4.13245openalex-snapshot
Physiology‐based pharmacokinetic model with relative transcriptomics to evaluate tissue distribution and receptor occupancy of anifrolumab
inferred← citeshttps://doi.org/10.1002/psp4.70043openalex-snapshot
An Integrative Mechanistic Model of Type 1 IFN ‐Mediated Inflammation in Systemic Lupus Erythematosus
inferred← citeshttps://doi.org/10.1002/rai2.12051openalex-snapshot
Identification and functional analysis of shared gene signatures between systemic lupus erythematosus and Sjögren's syndrome
inferred← citeshttps://doi.org/10.1002/rai2.70014openalex-snapshot
Efficacy and safety of anifrolumab across organ domains of systemic lupus erythematosus: A systematic review and meta‐analysis
inferred← citeshttps://doi.org/10.1002/sim.8740openalex-snapshot
Understanding and adjusting for the selection bias from a proof‐of‐concept study to a more confirmatory study
inferred← citeshttps://doi.org/10.1007/164_2021_551openalex-snapshot
Immunosuppression in Rheumatologic and Auto-immune Disease
inferred← citeshttps://doi.org/10.1007/978-3-030-56824-5_11openalex-snapshot
Immune-Related Adverse Events with Other Cancer Immunotherapies
inferred← citeshttps://doi.org/10.1007/978-3-030-73303-2_18openalex-snapshot
Metrics and Outcomes of SLE Clinical Trials
inferred← citeshttps://doi.org/10.1007/978-3-030-73303-2_20openalex-snapshot
Socioeconomic Impact of SLE: Metrics Utilized in the Determination of Direct and Indirect Costs and Future Directions
inferred← citeshttps://doi.org/10.1007/978-3-030-85161-3_1openalex-snapshot
Advances in Translational Science to Identify New Therapies for Systemic Lupus Erythematosus
inferred← citeshttps://doi.org/10.1007/978-3-030-85161-3_10openalex-snapshot
Balancing Strategies: GC and GILZ Axis
inferred← citeshttps://doi.org/10.1007/978-3-030-85161-3_5openalex-snapshot
Therapeutic Modulation of the Interferon Pathway in Systemic Lupus Erythematosus
inferred← citeshttps://doi.org/10.1007/978-3-031-04935-4_13openalex-snapshot
When the Illness Has No Name: Focus on Clinical Trials in Systemic Lupus Erythematosus
inferred← citeshttps://doi.org/10.1007/978-3-031-11665-0_26openalex-snapshot
Lupus Nephritis
inferred← citeshttps://doi.org/10.1007/978-3-031-24297-7_29-1openalex-snapshot
Molecular Targeted Therapies in Systemic Autoimmune Diseases
inferred← citeshttps://doi.org/10.1007/978-3-031-60006-7_29openalex-snapshot
Molecular Targeted Therapies in Systemic Autoimmune Diseases
inferred← citeshttps://doi.org/10.1007/978-3-032-12937-6_3openalex-snapshot
Systemic Lupus Erythematosus
inferred← citeshttps://doi.org/10.1007/978-3-662-60410-6_13openalex-snapshot
Studiendesign/Protokolle und Therapiesteuerung in der pädiatrischen Rheumatologie
inferred← citeshttps://doi.org/10.1007/978-3-662-60410-6_24openalex-snapshot
Weiterentwicklung in der Therapie rheumatischer Erkrankungen bei Kindern und Jugendlichen
inferred← citeshttps://doi.org/10.1007/978-3-662-60410-6_40openalex-snapshot
Dermatomyositis bei Kindern und Jugendlichen
inferred← citeshttps://doi.org/10.1007/978-3-662-60411-3_13-1openalex-snapshot
Studiendesign/Protokolle und Therapiesteuerung in der pädiatrischen Rheumatologie
inferred← citeshttps://doi.org/10.1007/978-3-662-60411-3_24-1openalex-snapshot
Weiterentwicklung in der Therapie rheumatischer Erkrankungen bei Kindern und Jugendlichen
inferred← citeshttps://doi.org/10.1007/978-3-662-60411-3_40-1openalex-snapshot
Dermatomyositis bei Kindern und Jugendlichen
inferred← citeshttps://doi.org/10.1007/978-981-16-7200-2_6openalex-snapshot
Biologics in Systemic Lupus Erythematosus (SLE)
inferred← citeshttps://doi.org/10.1007/978-981-16-7200-2_9openalex-snapshot
Biologics in Idiopathic Inflammatory Myopathies
inferred← citeshttps://doi.org/10.1007/978-981-19-5595-2_5openalex-snapshot
Plasmacytoid Dendritic Cells in Autoimmunity
inferred← citeshttps://doi.org/10.1007/978-981-19-5595-2_9openalex-snapshot
Therapeutic Targeting of Plasmacytoid Dendritic Cells
inferred← citeshttps://doi.org/10.1007/s00005-022-00647-8openalex-snapshot
New Treatment Options in Lupus Nephritis
inferred← citeshttps://doi.org/10.1007/s00105-021-04794-5openalex-snapshot
Systemischer Lupus erythematodes
inferred← citeshttps://doi.org/10.1007/s00105-024-05413-9openalex-snapshot
Monoklonale Antikörper für entzündliche, autoimmune und onkologische Hauterkrankungen
inferred← citeshttps://doi.org/10.1007/s00108-021-00948-8openalex-snapshot
Systemischer Lupus erythematodes
inferred← citeshttps://doi.org/10.1007/s00108-021-01249-wopenalex-snapshot
Biologika bei Kollagenosen und Vaskulitiden
inferred← citeshttps://doi.org/10.1007/s00108-021-01250-3openalex-snapshot
Innovationen in der Arzneimitteltherapie des systemischen Lupus erythematodes
inferred← citeshttps://doi.org/10.1007/s00108-023-01489-yopenalex-snapshot
Lupusnephritis – von der Diagnose zur Therapie
inferred← citeshttps://doi.org/10.1007/s00108-023-01624-9openalex-snapshot
Was ist gesichert in der Therapie des systemischen Lupus erythematodes?
inferred← citeshttps://doi.org/10.1007/s00108-025-02053-6openalex-snapshot
Systemischer Lupus erythematodes – Pathogenese, klinische Präsentation, Diagnostik und Management
inferred← citeshttps://doi.org/10.1007/s00109-024-02424-wopenalex-snapshot
Emerging therapeutic targets in systemic sclerosis
inferred← citeshttps://doi.org/10.1007/s00112-023-01787-7openalex-snapshot
Interferone als Schlüsselfaktoren für die Pathogenese, Diagnostik und Therapie
inferred← citeshttps://doi.org/10.1007/s00125-024-06339-6openalex-snapshot
Leveraging artificial intelligence and machine learning to accelerate discovery of disease-modifying therapies in type 1 diabetes
inferred← citeshttps://doi.org/10.1007/s00210-022-02250-2openalex-snapshot
A year in pharmacology: new drugs approved by the US Food and Drug Administration in 2021
inferred← citeshttps://doi.org/10.1007/s00296-022-05133-0openalex-snapshot
Tailored treatment strategies and future directions in systemic lupus erythematosus
inferred← citeshttps://doi.org/10.1007/s00296-023-05306-5openalex-snapshot
Current treatment of systemic lupus erythematosus: a clinician's perspective
inferred← citeshttps://doi.org/10.1007/s00296-024-05593-6openalex-snapshot
No clear influence of treatment escalation on flare prevention in serologically active clinically quiescent patients with systemic lupus erythematosus: a retrospective cohort study
inferred← citeshttps://doi.org/10.1007/s00296-025-05840-4openalex-snapshot
Novel association of chilblains with inflammatory arthritis- series of three cases and review of literature
inferred← citeshttps://doi.org/10.1007/s00296-026-06125-0openalex-snapshot
Targeting type I interferon in lupus panniculitis: a case-based systematic literature review
inferred← citeshttps://doi.org/10.1007/s00393-020-00767-6openalex-snapshot
Biologika und „small molecules“ beim systemischen Lupus erythematodes
inferred← citeshttps://doi.org/10.1007/s00393-020-00788-1openalex-snapshot
Neue Therapien beim systemischen Lupus erythematodes
inferred← citeshttps://doi.org/10.1007/s00393-020-00928-7openalex-snapshot
Anifrolumab for the treatment of active systemic lupus erythematosus: a meta-analysis of randomized controlled trials
inferred← citeshttps://doi.org/10.1007/s00393-021-00981-wopenalex-snapshot
Deeskalation und glukokortikoidfreie Therapie bei SLE
inferred← citeshttps://doi.org/10.1007/s00393-022-01281-7openalex-snapshot
Nierenbeteiligung bei Kollagenosen
inferred← citeshttps://doi.org/10.1007/s00393-023-01409-3openalex-snapshot
Therapeutische Antikörper in der Rheumatologie
inferred← citeshttps://doi.org/10.1007/s00393-024-01544-5openalex-snapshot
Die 2023 EULAR-Empfehlungen zur Behandlung des systemischen Lupus erythematodes – Implikationen für die Versorgung in Deutschland
inferred← citeshttps://doi.org/10.1007/s00393-024-01551-6openalex-snapshot
Was ist gesichert in der Therapie des systemischen Lupus erythematodes?
inferred← citeshttps://doi.org/10.1007/s00393-025-01760-7openalex-snapshot
Indirect comparative efficacy and safety of belimumab vs. anifrolumab in systemic lupus erythematosus and lupus nephritis: a meta-analysis of randomized trials
inferred← citeshttps://doi.org/10.1007/s00393-025-01772-3openalex-snapshot
Interferon-Scores im Management rheumatischer Systemerkrankungen
inferred← citeshttps://doi.org/10.1007/s00393-026-01779-4openalex-snapshot
Warum das C-reaktive Protein beim SLE (meist) nicht hoch ist
inferred← citeshttps://doi.org/10.1007/s00393-026-01838-wopenalex-snapshot
Methodological concerns and data discrepancies in the indirect treatment comparison of belimumab and anifrolumab
inferred← citeshttps://doi.org/10.1007/s00403-026-04743-zopenalex-snapshot
Trigger factors in systemic lupus erythematosus and atopic dermatitis: differences and similarities
inferred← citeshttps://doi.org/10.1007/s00467-020-04686-1openalex-snapshot
Kidney outcomes for children with lupus nephritis
inferred← citeshttps://doi.org/10.1007/s10067-020-05526-1openalex-snapshot
Interferon-directed therapies for the treatment of systemic lupus erythematosus: a critical update
inferred← citeshttps://doi.org/10.1007/s10067-023-06559-yopenalex-snapshot
Bortezomib is efficacious in the treatment of severe childhood-onset neuropsychiatric systemic lupus erythematosus with psychosis: a case series and mini-review of B-cell immunomodulation in antibody-mediated diseases
inferred← citeshttps://doi.org/10.1007/s10067-023-06597-6openalex-snapshot
Characterization of virus-mediated autoimmunity and the consequences for pathological process in patients with systemic lupus erythematosus
inferred← citeshttps://doi.org/10.1007/s10067-023-06645-1openalex-snapshot
Potential relevance of type I interferon-related biomarkers for the management of polygenic autoimmune rheumatic diseases with childhood onset
inferred← citeshttps://doi.org/10.1007/s10067-023-06728-zopenalex-snapshot
Bibliometric analysis of global literature productivity in systemic lupus erythematosus from 2013 to 2022
inferred← citeshttps://doi.org/10.1007/s10067-024-07236-4openalex-snapshot
The importance of developing reproducible primary endpoints for clinical trials in systemic lupus erythematosus
inferred← citeshttps://doi.org/10.1007/s10067-025-07674-8openalex-snapshot
Knowledge mapping of plasmacytoid dendritic cells in systemic lupus erythematosus: a bibliometric analysis (2004–2023)
inferred← citeshttps://doi.org/10.1007/s10067-025-07882-2openalex-snapshot
Predictors of adverse pregnancy outcomes in systemic lupus erythematosus: A retrospective cohort study
inferred← citeshttps://doi.org/10.1007/s10067-026-08455-7openalex-snapshot
Real-world outcomes after anifrolumab initiation in systemic lupus erythematosus: a pragmatic treat-to-target analysis
inferred← citeshttps://doi.org/10.1007/s10157-026-02863-4openalex-snapshot
Epidemiological analysis of kidney involvement in systemic lupus erythematosus using the national database of designated intractable diseases of Japan: a cross-sectional study of renewal applicants
inferred← citeshttps://doi.org/10.1007/s10238-023-00988-4openalex-snapshot
Differences and similarities in cytokine profiles of macrophage activation syndrome in systemic lupus erythematosus and adult-onset Still’s disease
inferred← citeshttps://doi.org/10.1007/s10238-023-01215-wopenalex-snapshot
COX5A as a potential biomarker for disease activity and organ damage in lupus
inferred← citeshttps://doi.org/10.1007/s10405-025-00619-7openalex-snapshot
Pleuropulmonale Manifestationen bei systemischem Lupus erythematodes
inferred← citeshttps://doi.org/10.1007/s10753-021-01455-6openalex-snapshot
Understanding Accelerated Atherosclerosis in Systemic Lupus Erythematosus: Toward Better Treatment and Prevention
inferred← citeshttps://doi.org/10.1007/s10753-026-02519-1openalex-snapshot
Pharmacological Characterization of GLPG3667, a Tyrosine Kinase 2-Selective Inhibitor, for the Treatment of Inflammatory and Autoimmune Diseases
inferred← citeshttps://doi.org/10.1007/s10875-024-01826-2openalex-snapshot
Normalized Interferon Signatures and Clinical Improvements by IFNAR1 Blocking Antibody (Anifrolumab) in Patients with Type I Interferonopathies
inferred← citeshttps://doi.org/10.1007/s10875-024-01851-1openalex-snapshot
Anifrolumab in Monogenic Lupus caused by TREX1 Mutation
inferred← citeshttps://doi.org/10.1007/s11560-021-00519-wopenalex-snapshot
Systemischer Lupus erythematodes
inferred← citeshttps://doi.org/10.1007/s11560-021-00523-0openalex-snapshot
Lupus und Nierenbeteiligung
inferred← citeshttps://doi.org/10.1007/s11560-025-00890-yopenalex-snapshot
Update Lupusnephritis
inferred← citeshttps://doi.org/10.1007/s11655-021-3497-0openalex-snapshot
Chinese Herbal Medicine for Systemic Lupus Erythematosus: A Systematic Review and Meta-analysis of Randomized, Placebo-Controlled Trials
inferred← citeshttps://doi.org/10.1007/s11883-023-01149-4openalex-snapshot
Atherosclerosis in Systemic Lupus Erythematosus
inferred← citeshttps://doi.org/10.1007/s11914-026-00960-7openalex-snapshot
Interferon–JAK–STAT Axis in Bone Metabolism
inferred← citeshttps://doi.org/10.1007/s11926-020-00906-7openalex-snapshot
An Update on the Diagnosis and Management of Lupus Nephritis
inferred← citeshttps://doi.org/10.1007/s11926-020-00946-zopenalex-snapshot
An Update on the Pathogenesis of Cutaneous Lupus Erythematosus and Its Role in Clinical Practice
inferred← citeshttps://doi.org/10.1007/s11926-021-01014-wopenalex-snapshot
Updates on Clinical Trials in Systemic Lupus Erythematosus
inferred← citeshttps://doi.org/10.1007/s11926-023-01125-6openalex-snapshot
Role of IFN-α in Rheumatoid Arthritis
inferred← citeshttps://doi.org/10.1007/s11926-025-01207-7openalex-snapshot
Juvenile-onset Systemic Lupus Erythematosus: Recent Advances in Pathogenesis and Treatment
inferred← citeshttps://doi.org/10.1007/s12016-020-08798-2openalex-snapshot
Type I Interferons in the Pathogenesis and Treatment of Autoimmune Diseases
inferred← citeshttps://doi.org/10.1007/s12016-020-08817-2openalex-snapshot
Management of Severe Refractory Systemic Lupus Erythematosus: Real-World Experience and Literature Review
inferred← citeshttps://doi.org/10.1007/s12016-021-08891-0openalex-snapshot
Therapeutic Approaches to Systemic Sclerosis: Recent Approvals and Future Candidate Therapies
inferred← citeshttps://doi.org/10.1007/s12016-024-09020-3openalex-snapshot
Clinical and Pathophysiological Tangles Between Allergy and Autoimmunity: Deconstructing an Old Dichotomic Paradigm
inferred← citeshttps://doi.org/10.1007/s12016-025-09025-6openalex-snapshot
Macrophages Unmasked: Their Pivotal Role in Driving Atherosclerosis in Systemic Lupus Erythematosus
inferred← citeshttps://doi.org/10.1007/s12016-025-09051-4openalex-snapshot
Exploring Gut Microbiota in Systemic Lupus Erythematosus: Insights and Biomarker Discovery Potential
inferred← citeshttps://doi.org/10.1007/s12016-025-09082-xopenalex-snapshot
Efficacy and Safety of Biologics for Systemic Lupus Erythematosus (SLE): A Systematic Review and Network Meta-Analysis
inferred← citeshttps://doi.org/10.1007/s12016-026-09165-3openalex-snapshot
Vitiligo as a Failure of Immune Resolution and Tissue Regeneration: From Stress Signals to Targeted Immune Modulation
inferred← citeshttps://doi.org/10.1007/s12325-025-03299-0openalex-snapshot
Design of Two Randomized, Placebo-Controlled, Phase 3 Trials of Deucravacitinib, an Oral, Selective, Allosteric TYK2 Inhibitor, in Systemic Lupus Erythematosus
inferred← citeshttps://doi.org/10.1007/s12519-022-00679-2openalex-snapshot
Clinical spectrum and currently available treatment of type I interferonopathy Aicardi–Goutières syndrome
inferred← citeshttps://doi.org/10.1007/s12519-025-00913-7openalex-snapshot
Innovative therapies for childhood-onset systemic lupus erythematosus
inferred← citeshttps://doi.org/10.1007/s12688-022-00540-4openalex-snapshot
Innovationen in der Arzneimitteltherapie des systemischen Lupus erythematodes
inferred← citeshttps://doi.org/10.1007/s12688-023-00666-zopenalex-snapshot
Lupusnephritis – von der Diagnose zur Therapie
inferred← citeshttps://doi.org/10.1007/s13318-021-00706-zopenalex-snapshot
Identifying Safety Thresholds for Immunosuppressive Drugs: Applying Insights from Primary Antibody Deficiencies to Mitigate Adverse Events in Secondary Antibody Deficiencies Using Mathematical Modeling of Preclinical and Early Clinical Data
inferred← citeshttps://doi.org/10.1007/s13577-026-01381-5openalex-snapshot
Pathogenesis and therapeutic strategies for neuropsychiatric lupus centered on innate immune activation
inferred← citeshttps://doi.org/10.1007/s15011-024-6432-9openalex-snapshot
Neue Wirkstoffe ermöglichen gute Krankheitskontrolle
inferred← citeshttps://doi.org/10.1007/s40257-023-00774-8openalex-snapshot
Cutaneous Lupus Erythematosus: An Update on Pathogenesis and Future Therapeutic Directions
inferred← citeshttps://doi.org/10.1007/s40259-020-00405-2openalex-snapshot
Targeted Biologic Therapy for Systemic Lupus Erythematosus: Emerging Pathways and Drug Pipeline
inferred← citeshttps://doi.org/10.1007/s40259-023-00597-3openalex-snapshot
Lupus Nephritis: New and Emerging Biologic and Targeted Therapies
inferred← citeshttps://doi.org/10.1007/s40262-023-01238-2openalex-snapshot
Clinical Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Anifrolumab
inferred← citeshttps://doi.org/10.1007/s40265-021-01604-zopenalex-snapshot
Anifrolumab: First Approval
inferred← citeshttps://doi.org/10.1007/s40265-022-01715-1openalex-snapshot
Lupus Nephritis: Improving Treatment Options
inferred← citeshttps://doi.org/10.1007/s40265-023-01856-xopenalex-snapshot
Targeted Small Molecules for Systemic Lupus Erythematosus: Drugs in the Pipeline
inferred← citeshttps://doi.org/10.1007/s40265-024-02043-2openalex-snapshot
Targeting Interferon Signalling in Systemic Lupus Erythematosus: Lessons Learned
inferred← citeshttps://doi.org/10.1007/s40265-025-02156-2openalex-snapshot
Revolutionary Changes in the Management of Lupus Nephritis: Towards De-Glucocorticoid or No-Glucocorticoid
inferred← citeshttps://doi.org/10.1007/s40266-021-00911-0openalex-snapshot
Neuropsychiatric Systemic Lupus Erythematosus in Older Adults: Diagnosis and Management
inferred← citeshttps://doi.org/10.1007/s40267-022-00925-7openalex-snapshot
Anifrolumab in systemic lupus erythematosus: a profile of its use
inferred← citeshttps://doi.org/10.1007/s40272-021-00484-wopenalex-snapshot
Managing Antiphospholipid Syndrome in Children and Adolescents: Current and Future Prospects
inferred← citeshttps://doi.org/10.1007/s40290-026-00631-zopenalex-snapshot
Placebo Response in Randomised Controlled Trials of Systemic Therapies for Cutaneous Lupus Erythematosus: A Systematic Review and Meta-Analysis
inferred← citeshttps://doi.org/10.1007/s40674-020-00155-wopenalex-snapshot
Janus Kinase Inhibition and SLE: Is this a Plausible Treatment Option for SLE?
inferred← citeshttps://doi.org/10.1007/s40674-025-00224-yopenalex-snapshot
Defining Disease Activity in Systemic Sclerosis
inferred← citeshttps://doi.org/10.1007/s40674-025-00235-9openalex-snapshot
Risk of Herpes Zoster and Opportunistic Infections with Treatments for Autoimmune Rheumatic Disease
inferred← citeshttps://doi.org/10.1007/s40744-020-00212-9openalex-snapshot
Systemic Lupus Erythematosus (SLE) Therapy: The Old and the New
inferred← citeshttps://doi.org/10.1007/s40744-021-00404-xopenalex-snapshot
Differential Changes in ACPA Fine Specificity and Gene Expression in a Randomized Trial of Abatacept and Adalimumab in Rheumatoid Arthritis
inferred← citeshttps://doi.org/10.1007/s40744-022-00442-zopenalex-snapshot
A Narrative Literature Review Comparing the Key Features of Musculoskeletal Involvement in Rheumatoid Arthritis and Systemic Lupus Erythematosus
inferred← citeshttps://doi.org/10.1007/s40744-023-00601-wopenalex-snapshot
Targeting DORIS Remission and LLDAS in SLE: A Review
showing the first 200 of 1381
Editorial review for independent work. ICSAC — the Institute for Complexity Science and Advanced Computing — runs a structured editorial panel for researchers publishing outside journals, and publishes on CiteStamp rails. Submission is free and goes through ORCID: icsacinstitute.org/submit.